Following a lengthy discovery period, the lab is asking a South Carolina federal district court to find in its favor and decide that its negligence did not result in the death of Williams' son.
The company expects that Blueprint's informatics capabilities in particular will improve variant interpretation and reporting across all its genetic test offerings.
Revenues for the quarter were $1.93 billion, with the company attributing the growth to expanded access to insurer networks and good operational execution.
Memorial Hermann's outreach sites will transfer testing to Quest's Houston lab and the firm will also provide management services for the system's 21 hospital labs.
Blueprint provides 3,900 targeted single-gene and more than 200 panel tests covering 14 medical specialties, leveraging NGS and bioinformatics methods.
A pair of lawyers familiar with the case said that while ACLA might not win the legal battle, its lawsuit could aid efforts to get a legal fix to the law.
Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.
The investment bank cut its price target on Quest's shares and noted recently passed legislation that it believes will put pricing pressure on the company.
While legislation and lawsuits sought to blunt PAMA's impact, labs also employed new technologies and strategies to cope with anticipated price cuts.
The company intends to use the net proceeds to repay at maturity or redeem its $800 million aggregate principal amount of senior notes due in 2020.